ArticleACS omega2026
Lathyrol Targets G6PD to Disrupt Redox Homeostasis in Non-Small Cell Lung Cancer.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lathyrol, a bioactive natural compound derived from plants of the Euphorbiaceae family, exhibits antitumor activity, and its molecular targets and underlying mechanisms remain incompletely understood. In this study, thermal proteome profiling (TPP) was applied to systematically identify lathyrol-binding proteins in non-small cell lung cancer (NSCLC) cells. TPP analysis identified glucose-6-phosphate dehydrogenase (G6PD) as a candidate target of lathyrol. A cellular thermal shift assay (CETSA) confirmed increased thermal stability of G6PD upon treatment. Molecular docking indicated a potential interaction between lathyrol and G6PD. The peptide-centric local stability assay (PELSA) revealed localized conformational changes in the C-terminal region of G6PD consistent with the predicted interaction interface. Enzymatic assays showed reduced G6PD activity accompanied by decreased intracellular NADPH levels. Quantitative proteomics indicated alterations in the pathways associated with glucose metabolism and redox regulation. These findings identify G6PD as a functional target of lathyrol in NSCLC cells and link its inhibition to disruption of cellular redox balance and metabolic homeostasis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.